The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-03. Anything still debated is marked as such rather than presented as settled.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
A system of measure for timber in the round (standing or felled), now largely superseded by the metric system except in measuring hardwoods in certain countries. Its purpose is to estimate the value of sawn timber in a log, by measuring the unsawn log and allowing for wastage in the mill. Following the so-called "quarter-girth formula" (the square of one quarter of the circumference in inches multiplied by 1⁄144 of the length in feet), the notional log is four feet in circumference, one inch of which yields the hoppus board foot, 1 foot yields the hoppus foot, and 50 feet yields a hoppus ton. This translates to a hoppus foot being equal to 1.273 cubic feet (2,200 in3; 0.0360 m3). The hoppus board foot, when milled, yields about one board foot. The volume yielded by the quarter-girth formula is 78.54% of cubic measure (i.e. 1 ft3 = 0.7854 h ft; 1 h ft = 1.273 ft3).
=== Relapse === Rates of relapse after treatment range 30–72% over a period of 2–26 months, with a rate of approximately 50% in 12 months after weight restoration. Relapse occurs in approximately a third of people in hospital, and is greatest in the first six to eighteen months after release from an institution. BMI or measures of body fat and leptin levels at discharge were the strongest predictors of relapse, as well as signs of eating psychopathology at discharge. Duration of illness, age, severity, the proportion of AN binge-purge subtype, and presence of comorbidities are also contributing factors.
John Barry Larson (born July 22, 1948) is an American politician and businessman who has been serving as the U.S. representative for Connecticut's 1st congressional district since 1999. The district is based in the state capital, Hartford. A member of the Democratic Party, Larson chaired the House Democratic Caucus during the 111th and 112th United States Congress. Larson was first elected to Congress in 1998, serving fourteen consecutive terms in the House. He attempted to seek a fifteenth term, but he was defeated in the 2026 Democratic primary by former Hartford mayor Luke Bronin.
In the case of active targeting, quantum dots are functionalized with tumor-specific binding sites to selectively bind to tumor cells. Passive targeting uses the enhanced permeation and retention of tumor cells for the delivery of quantum dot probes. Fast-growing tumor cells typically have more permeable membranes than healthy cells, allowing the leakage of small nanoparticles into the cell body. Moreover, tumor cells lack an effective lymphatic drainage system, which leads to subsequent nanoparticle accumulation. Quantum dot probes exhibit in vivo toxicity. For example, CdSe nanocrystals are highly toxic to cultured cells under UV illumination, because the particles dissolve, in a process known as photolysis, to release toxic cadmium ions into the culture medium. In the absence of UV irradiation, however, quantum dots with a stable polymer coating have been found to be essentially nontoxic. Hydrogel encapsulation of quantum dots allows for quantum dots to be introduced into a stable aqueous solution, reducing the possibility of cadmium leakage. Then again, only little is known about the excretion process of quantum dots from living organisms. In another potential application, quantum dots are being investigated as the inorganic fluorophore for intra-operative detection of tumors using fluorescence spectroscopy. Delivery of undamaged quantum dots to the cell cytoplasm has been a challenge with existing techniques.
== Function == The TAP transporter is found in the ER lumen associated with the peptide-loading complex (PLC). This complex of β2 microglobulin, calreticulin, ERp57, TAP, tapasin, and MHC class I acts to keep hold of MHC molecules until they have been fully loaded with peptides.
Sources: en.wikipedia.org
Portuguese cuisine is influenced by both the Mediterranean and Atlantic diets. Seafood, brassicas, potatoes, bread, dairy, and olive oil are traditional staples. Bacalhau has such a broad presence in Portugal that it is considered a national dish, along with the pastel de nata. Traditional Portuguese sweets are known as conventual sweets. Large quantities of sugar and eggs are used. Popular Portuguese beverages include its wines, a craft that is well establish since the 7th century, and of which are such examples as Port and Madeira. Beer has been brewed in Portugal since the Chalcolithic. Tea has been produced on São Miguel Island since the 19th century.
== Distribution and habitat == The Liliaceae are widely distributed, but mainly in the temperate regions of the Northern Hemisphere. The centre of diversity is from southwest Asia to China. Their distribution is diverse, mainly in plains, steppes, and alpine meadows, but also in deciduous forests, Mediterranean scrub and arctic tundra. Tulipa and Gagea provide examples of ornamental geophyte biomorphological types representing continental thermoperiodic zones (Irano-Turanian region), characterised by cessation of underground growth at high temperatures in early summer and requiring low winter temperatures for spring flowering. While some genera are shade-dwelling, such as the Medeoleae, and Streptopoideae, Tricyrtis, and Cardiocrinum, others prefer a more open habitat.
extracellular matrix (ECM) Also intercellular matrix. The network of interacting macromolecules and minerals secreted by and existing outside of and between cells in multicellular structures such as tissues and biofilms, forming a hydrated, mesh-like, semi-solid suspension which not only holds the cells together in an organized fashion but also provides structural and biochemical support, acting as an elastic, compressible buffer against external stresses as well as both regulating and influencing numerous aspects of cell behavior, among them cell adhesion, motility, metabolism, division, and cell-to-cell communication. The composition and properties of the ECM vary enormously between organisms and tissue types, but generally it takes the form of a polysaccharide gel in which various fibrous proteins (especially collagen and elastin), enzymes, and glycoproteins are embedded. Cells themselves both produce the matrix components and respond constantly to local matrix composition, a source of environmental feedback which is critical for differentiation, tissue organization, and development.
The earliest known reference to morphine can be traced back to Theophrastus in the 3rd century BC, however, possible references to morphine may go as far back as 2100 BC as Sumerian clay tablets which records lists of medical prescriptions including opium-based cures. An opium-based elixir has been ascribed to alchemists of Byzantine times, but the specific formula was lost during the Ottoman conquest of Constantinople (Istanbul). Around 1522, Paracelsus made reference to an opium-based elixir that he called laudanum from the Latin word laudāre, meaning "to praise". He described it as a potent painkiller but recommended that it be used sparingly. The recipe given differs substantially from that of modern-day laudanum. Morphine was discovered as the first active alkaloid extracted from the opium poppy plant in December 1804 in Paderborn by German pharmacist Friedrich Sertürner. Sertürner noticed the compound induced drowsiness in rats and stray dogs and he reported his findings in 1805. In 1817, Sertürner reported experiments in which he administered morphine to himself, three young boys, three dogs, and a mouse; all four people almost died. Sertürner originally named the substance morphium after the Greek god of dreams, Morpheus, as it has a tendency to cause sleep. Sertürner's morphium was six times stronger than opium. He hypothesized that, because lower doses of the drug were needed, it would be less addictive.
Sources: en.wikipedia.org
=== Early life, start of career and Basel === Photaki was born in Corinth in 1921 and finished her secondary education at the 2nd Girls' Gymnasium of Athens in 1938. In the same year she enrolled at the Department of Chemistry in the University of Athens, where she specialised in Organic chemistry under the mentorship of Leonidas Zervas. Her studies were interrupted during the Axis occupation of Greece when the Laboratory of Organic Chemistry was destroyed and Zervas was imprisoned as a member of the Greek Resistance. Photaki was finally awarded her degree summa cum laude in 1946 and subsequently continued her postgraduate studies under Zervas, earning her PhD in 1950 with a dissertation regarding glucosamine. Concurrently, she held a paid laboratory assistant position at the university already from 1943, carrying on as a research assistant until 1953. In 1953, Photaki was awarded a scholarship to conduct research in Basel after examinations by the Greek State Scholarships Foundation. At the University of Basel she worked in the Laboratory of Organic Chemistry, at the time headed by Nobel laureate Tadeusz Reichstein. For the first two years of her stay (1953–1955) she was part of the Max Brenner research group, later moving as an independent scientific associate of Hans Erlenmeyer. Upon returning to Greece, she initially worked at the biochemical lab of the Evangelismos Hospital before being invited by Zervas to the nascent National Hellenic Research Foundation (NHRF) which he had helped found.
== Human proteins containing this domain == BMP binding endothelial regulator (BMPER) Cysteine-rich motor neuron 1 protein (CRIM1) Extracellular matrix protein 2 (ECM2) Fraser extracellular matrix complex subunit 1 (FRAS1) Neural EGFL like 1 (NELL1) Neural EGFL like 2 (NELL2) Peroxidasin like (PXDNL) Von Willebrand factor C and EGF domain-containing protein (VWCE) Von Willebrand factor (VWF)
Collagen is a structural protein, often referred to as "the steel of biological materials". There are multiple types of collagen: Type I (comprising skin, tendons and ligaments, vasculature and organs, as well as teeth and bone and artery walls); Type II (a component in cartilage); Type III (often found in reticular fibers); and others. Collagen has a hierarchical structure, forming triple helices, fibrils, and fibers. Collagen are a family of protein that support and strengthen many tissues in the body.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.